Literature DB >> 14678602

Assessing human alloimmunization as a strategy for inducing HIV type 1 neutralizing anti-HLA responses.

Jonathan G Leith1, David A Clark, Thomas J Matthews, Kenneth L Rosenthal, Mark A Luscher, Brian H Barber, Kelly S MacDonald.   

Abstract

Xenovaccination of rhesus macaques with human HLA Class I and II proteins has been demonstrated to elicit protective immunity against challenge with SIV grown in human cells. To determine if alloimmunization in humans could lead to protective immunity against HIV-1, we prospectively followed a small group of women receiving whole-cell alloimmunization in the form of leukocyte immunotherapy for recurrent spontaneous abortion. Whole-cell vaccine recipients and their respective partners (referred to as donors) provided pre- and postimmune blood samples for analysis. Study participants were HLA typed by sequence-specific PCR and antibodies specific for HLA Class I and II antigens were measured in recipient plasma. To determine if anti-HLA antibody responses detected in recipient plasma samples were capable of neutralizing HIV-1 in vitro, we grew laboratory strain HIV-1(IIIB) and primary isolate HIV-1(301660) in donor-derived CD4(+) T lymphocytes. The ability of purified whole IgG from responding patients to neutralizing infectivity of the respective donor-derived virus was then assayed in vitro. All donor-recipient pairs were determined to be HLA discordant for at least one Class I and one Class II locus. Two of seven female recipients in total made strong anti-HLA antibody responses specific to the HLA haplotype of the male donor in response to the alloimmunization regimen. For one recipient, IgG antibodies specific for donor HLA Class I and II antigens were able to neutralize both HIV-1(IIIB) and a primary isolate HIV-1(301660). In addition polyclonal anti-HLA class II antibodies against a single determinant (DR4) of this donor were also neutralizing. In contrast, the other recipient exhibiting antibodies only against donor HLA Class I antigens did not neutralize HIV-1(IIIB). Using samples from a small number of women undergoing leukocyte immunotherapy, we have demonstrated for the first time that allele-specific anti-HLA antibodies elicited through human alloimmunization are capable of neutralizing HIV-1 in vitro.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14678602     DOI: 10.1089/088922203322588305

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  12 in total

1.  Immunization with recombinant HLA classes I and II, HIV-1 gp140, and SIV p27 elicits protection against heterologous SHIV infection in rhesus macaques.

Authors:  Andreas Mörner; Marianne Jansson; Evelien M Bunnik; Jørgen Schøller; Robert Vaughan; Yufei Wang; David C Montefiori; Nel Otting; Ronald Bontrop; Lesley A Bergmeier; Mahavir Singh; Richard T Wyatt; Hanneke Schuitemaker; Gunnel Biberfeld; Rigmor Thorstensson; Thomas Lehner
Journal:  J Virol       Date:  2011-04-13       Impact factor: 5.103

2.  Working group consultation: alloimmunity as a vaccine approach against HIV/AIDS: National Institutes of Health Meeting Report, May 24, 2012.

Authors:  Anjali Singh; Jon Warren; Alan Schultz; Charles J Hackett; Opendra Sharma
Journal:  AIDS Res Hum Retroviruses       Date:  2013-04-23       Impact factor: 2.205

Review 3.  Survivors Remorse: antibody-mediated protection against HIV-1.

Authors:  George K Lewis; Marzena Pazgier; Anthony L DeVico
Journal:  Immunol Rev       Date:  2017-01       Impact factor: 12.988

4.  Quantitation of HLA proteins incorporated by human immunodeficiency virus type 1 and assessment of neutralizing activity of anti-HLA antibodies.

Authors:  Samir K Lakhashe; Madhuri R Thakar; K E Bharucha; Ramesh S Paranjape
Journal:  J Virol       Date:  2007-10-17       Impact factor: 5.103

5.  Isolation of a monoclonal antibody from a phage display library binding the rhesus macaque MHC class I allomorph Mamu-A1*001.

Authors:  Nathan Holman; Jason T Weinfurter; Trevor R Harsla; Roger W Wiseman; Aaron J Belli; Anthony J Michaels; Keith A Reimann; Robert I DeMars; Matthew R Reynolds
Journal:  PLoS One       Date:  2017-07-18       Impact factor: 3.240

Review 6.  Development of a human leukocyte antigen-based HIV vaccine.

Authors:  Yufei Wang
Journal:  F1000Res       Date:  2018-06-22

7.  Greater ethnic diversity correlates with lower HIV prevalence in Africa: justification for an alloimmunity vaccine.

Authors:  Christopher Zamani; Jared D Elzey; James Ek Hildreth
Journal:  HIV AIDS (Auckl)       Date:  2013-04-12

Review 8.  The rise and fall of HIV in high-prevalence countries: a challenge for mathematical modeling.

Authors:  Nico J D Nagelkerke; Paul Arora; Prabhat Jha; Brian Williams; Lyle McKinnon; Sake J de Vlas
Journal:  PLoS Comput Biol       Date:  2014-03-13       Impact factor: 4.475

9.  Complement-mediated virus infectivity neutralisation by HLA antibodies is associated with sterilising immunity to SIV challenge in the macaque model for HIV/AIDS.

Authors:  Mark Page; Ruby Quartey-Papafio; Mark Robinson; Mark Hassall; Martin Cranage; James Stott; Neil Almond
Journal:  PLoS One       Date:  2014-02-14       Impact factor: 3.240

10.  Identifying a Minor Histocompatibility Antigen in Mauritian Cynomolgus Macaques Encoded by APOBEC3C.

Authors:  Jason T Weinfurter; Michael E Graham; Adam J Ericsen; Lea M Matschke; Sian Llewellyn-Lacey; David A Price; Roger W Wiseman; Matthew R Reynolds
Journal:  Front Immunol       Date:  2020-10-26       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.